ClinicalTrials.gg
CompletedNCT03408470Updated Jan 14, 2021

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

A Phase 1 interventional study of TD-1473 oral capsule and [14C]-TD-1473 IV bolus in Intestinal Disorders and Bowel Diseases, Inflammatory, sponsored by Theravance Biopharma. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-14.

Primary conditionInflammatory Bowel DiseasesRegistry: Intestinal DiseasesReclassifiedWhy we changed it
Registry
Intestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Inflammatory Bowel Diseases
Why
  1. The study's listed conditions name Inflammatory Bowel Diseases, a narrower term within Intestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Theravance Biopharma (part of Zymeworks) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
244th of 327
20 · median 50
Started
2018
with 23 others
Phase 1
44 of 463
6 open now
Registered
232nd of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 244th largest by enrollment of the 327 interventional ones that give a count, is one of 24 that started in 2018, is one of 44 in phase 1, and was the 232nd registered.

Inflammatory Bowel Diseases

1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects. Subjects in cohort 1 will receive a single oral dose of TD-1473 and a single intravenous bolus dose of [14C]-TD-1473. Subjects in cohort 2 will receive a single oral dose of [14C]-TD-1473 only.

03

Conditions studied

  • Intestinal Disorders
  • Bowel Diseases, Inflammatory

Browse trials for

Keywords

  • Absolute Bioavailability
  • ADME
  • Healthy Normal Males
04

In context

Inflammatory Bowel Diseases Reclassified

1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

This study's enrollment of 20 is below the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Theravance Biopharma is the lead sponsor of 47 studies on the registry; none are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.

First submitted before Theravance Biopharma became part of Zymeworks.

Compared within Inflammatory Bowel Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a healthy, nonsmoking male, 19 to 55 years old, inclusive
  • Subject has a (BMI) 19 to 32 kg/m2, inclusive, and weighs at least 50 kg
  • Subject is healthy as determined by the PI or designee based on medical history and physical examination performed at Screening and Day -1
  • Additional inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Subject has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas])
  • Subject has a known towards medications similar to TD 1473 or contained in TD 1473
  • Subject regularly works with ionizing radiation or radioactive material
  • Subject has been exposed to ionizing radiations, within 1 year prior to the start of the study, as external irradiation (i.e., radiological examination including CT scan, excluding dental radiography) or internal radiation (i.e., diagnostic nuclear medicine procedure) or have participated in a radiolabeled study in the last 12 months
  • Subject, who, for any reason, is deemed by the PI or designee or Sponsor to be inappropriate for this study or have any condition which would confound or interfere with the evaluation of the safety, tolerability, and PK of the drug or prevent compliance with the study protocol
  • Additional exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus

    Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473

    Drug: TD-1473 oral capsule · Drug: [14C]-TD-1473 IV bolus

  • Experimental
    [14C]-TD-1473 Oral Capsule

    Cohort 2 - One oral dose

    Drug: [14C]-TD-1473 Oral Capsule

Interventions

  • (Intervention description included in arm description)

  • Drug[14C]-TD-1473 IV bolus

    (Intervention description included in arm description)

  • (Intervention description included in arm description)

07

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) in Plasma

    Time frame: Up to 15 days

  2. Time to maximum observed concentration (tmax) in Plasma

    Time frame: Up to 15 days

  3. Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma

    Time frame: Up to 15 days

  4. Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma

    Time frame: Up to 15 days

  5. Apparent terminal elimination half-life (t1/2) in Plasma

    Time frame: Up to 15 days

  6. Apparent clearance (Cl/F) in Plasma

    Time frame: Up to 15 days

  7. Apparent volume of distribution (Vz/F) in Plasma

    Time frame: Up to 15 days

  8. Absolute bioavailability (%F) in Plasma

    Time frame: Up to 15 days

Secondary outcomes

  1. Amount excreted in urine (Aeu) over the sampling interval in Urine

    Time frame: Up to 15 days

  2. Renal clearance (CLr) in Urine

    Time frame: Up to 15 days

  3. The percent excreted in urine (%Feu) in Urine

    Time frame: Up to 15 days

  4. Amount excreted in feces (Aef) over the sampling interval in Feces

    Time frame: Up to 15 days

  5. The percent excreted in feces (%Fef)

    Time frame: Up to 15 days

Other outcomes

  1. Metabolites in Plasma

    TD 1473 metabolite profiling will be performed in plasma containing sufficient amounts of radioactivity

    Time frame: Up to 15 days

  2. Metabolites in Urine

    TD 1473 metabolite profiling will be performed in urine containing sufficient amounts of radioactivity

    Time frame: Up to 15 days

  3. Metabolites in Feces

    TD-1473 metabolite profiling will be performed in feces containing sufficient amounts of radioactivity

    Time frame: Up to 15 days

08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

References and documents

Individual participant data

Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Feb 2018, 0 months.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 0 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 24, 2018
StartActual
Jan 31, 2018
Primary completionActual
Feb 21, 2018
CompletionActual
Feb 21, 2018
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03408470
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Jan 31, 2018
Primary completion
Feb 21, 2018
Completion
Feb 21, 2018
Last update
Jan 14, 2021

Study contacts

Medical Monitor
study director · Theravance Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izencitinib

Start the discussion